Potential role of circulating microRNA-21 for hepatocellular carcinoma diagnosis: A meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Liao, Qibin ^a   Han, Peiyu ^a   Huang, Yue ^a   Wu, Zhitong ^a   Chen, Qing ^a   Li, Shanshan ^a   Ye, Jufeng ^a   Wu, Xianbo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; MICRORNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; EARLY CANCER; HUMAN; LIVER CELL CARCINOMA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER NEOPLASMS; META ANALYSIS;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICRORNAS;

EID: 84938651946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130677     Document Type: Article

References (36)

1. Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of Hepatocellular Carcinoma. Surgical oncology clinics of north America 24:1-17. doi: 10.1016/j.soc.2014.09.001 PMID: 25444466
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. Ca-a cancer journal for clinicians 65:87-108. doi: 10.3322/caac.21262 PMID: 25651787
3. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD (2009) Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 3: 353-367. doi: 10.1586/egh.09.35 PMID: 19673623
4. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127. doi: 10.1056/NEJMra1001683 PMID: 21992124
5. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008). Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752-1763. doi: 10.1053/j.gastro.2008.02.090 PMID: 18471552
6. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. (2009)Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30:37-47. doi: 10.1111/j.1365-2036.2009.04014.x PMID: 19392863
7. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update.Hepatology 53:1020-1022. doi: 10.1002/hep.24199 PMID: 21374666
8. Brenner DJ, Hall EJ (2007) Computed tomography - an increasing source of radiation exposure. N Engl J Med 357:2277-2284. PMID: 18046031
9. Corvalan AH (2012) Early diagnosis of hepatocellularcarcinoma by microRNAs: shining a light from thegenome's "dark matter". Dig Dis Sci. 57:2737-2739. doi: 10.1007/s10620-012-2384-0 PMID: 23014845
10. Miyazawa M, Torii T, Toshimitsu Y, Kamizasa N, Suzuki T, Shinozuka N, et al. (2006) Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts. J Clin Gastroenterol 40:555-557. PMID: 16825940
11. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, et al. (2010) Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers:analysis of 104 cases. J Surg Oncol 102:249-255. doi: 10.1002/jso.21624 PMID: 20740583
12. European Association for Study of Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 56:908-943. doi: 10.1016/j.jhep.2011.12.001 PMID: 22424438
13. Kloosterman W, Plasterk R (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450. PMID: 17011485
14. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. PMID: 17060945
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-10518. doi: 10.1073/pnas.0804549105 PMID: 18663219
16. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997-1006. doi: 10.1038/cr.2008.282 PMID: 18766170
17. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007) MiR-21-mediated tumor growth.Oncogene 26: 2799-2803. PMID: 17072344
18. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES (2008)Prognostic value of mature microRNA-21 and microRNA-205 overexpression in nonsmall cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54:1696-1704. doi: 10.1373/clinchem.2007.101741 PMID: 18719201
19. Schetter AJ, Leung SY, Sohn JJ, et al. (2008)MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436. doi: 10.1001/jama.299.4.425 PMID: 18230780
20. Shan L, Ji Q, Cheng G, Xia J, Liu D, Wu C, Zhu B, Ding Y (2015) Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer Biomark 15:47-56 doi: 10.3233/CBM-140437 PMID: 25524942
21. Zeng Z, Wang J, Zhao L, Hu P, Zhang H, et al. (2013) Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One 8:e73278. doi: 10.1371/journal.pone.0073278 PMID: 24023850
22. Yang X, Guo Y, Du Y, Yang J, Li S, et al. (2014) Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis. PLoS One 9:e97460. doi: 10.1371/journal.pone.0097460 PMID: 24865991
23. Xu J, Wu C, Che X, Wang L, Yu D, et al. (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50:136-42. doi: 10.1002/mc.20712 PMID: 21229610
24. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, et al. (2012) Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56:167-75. doi: 10.1016/j.jhep.2011.04.026 PMID: 21749846
25. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. (2012) Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2: e000825. doi: 10.1136/bmjopen-2012-000825 PMID: 22403344
26. Qin Z, Zhu X, Huang Y (2013) Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Sichuan Med J 34:1463-5.
27. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25. PMID: 14606960
28. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6: 31. PMID: 16836745
29. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11:193-206. PMID: 16784338
30. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893. PMID: 16085191
31. Kew MC (2010) Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 58 (4):273-277. doi: 10.1016/j.patbio.2010.01.005 PMID: 20378277
32. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (7):2557-2576. PMID: 17570226
33. Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5):v59e64. doi: 10.1093/annonc/mdq166 PMID: 20555104
34. Corvalan AH (2012) Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's "dark matter". Dig Dis Sci. 57:2737-2739. doi: 10.1007/s10620-012-2384-0 PMID: 23014845
35. Li BS, Zhao YL, Guo G, Li W, Zhu ED, et al. (2012) Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 7: e41629. doi: 10.1371/journal.pone.0041629 PMID: 22860003
36. Tang D, Shen Y, Wang M, Yang R, Wang Z, et al. (2013) Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Pre 22 (6):540-548. doi: 10.1097/CEJ.0b013e32835f3be9 PMID: 23462458